Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers ...

We look forward to utilizing this technology to treat our patients.” “Securing CE Mark approval for PerQseal Elite marks a major milestone for Vivasure and for patients undergoing complex ...

This novel algorithm offers a standardised assessment, helping emergency room doctors to make confident clinical decisions in ruling in or ruling out heart attacks (acute myocardial infarction ...

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC ...

BAAR, Switzerland - Novocure (NASDAQ: NVCR), a medical technology company with a market capitalization of $1.7 billion, has announced the CE Mark approval of Optune Lua for the treatment of ...

UK digital health firm Vinehealth has won a CE mark for a mobile app that helps cancer patients manage their medications and care, as well as a sister web-based app aimed at clinicians.

[1] European Union: EUR-Lex. Chest Pain Triage algorithm registration [Internet: accesses March 24, 2025] Chest Pain Triage algorithm is an in-vitro diagnostic (IVD) medical device CE-marked (NB 0123) ...